• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Significance of Extrachromosomal DNA in -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience.

作者信息

Aoki Yu, Hashimoto Tadayoshi, Takahashi Nobuyuki, Okunaka Mashiro, Mishima Saori, Kotani Daisuke, Kawazoe Akihito, Nakamura Yoshiaki, Nakayama Izuma, Kuboki Yasutoshi, Bando Hideaki, Kojima Takashi, Nakamura Nobuyuki, Sakamoto Naoya, Ishii Genichiro, Fujisawa Takao, Yoshino Takayuki, Arai Yasuhito, Shibata Tatsuhiro, Shitara Kohei

机构信息

Department of Medical Oncology, Tokyo Saiseikai Central Hospital, Tokyo, Japan.

Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

出版信息

JCO Precis Oncol. 2025 Aug;9:e2500033. doi: 10.1200/PO-25-00033. Epub 2025 Aug 18.

DOI:10.1200/PO-25-00033
PMID:40825170
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12369511/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/a37f909f1a9e/po-9-e2500033-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/8ed55d7d800a/po-9-e2500033-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/ce3da6820f44/po-9-e2500033-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/94b9bdf11452/po-9-e2500033-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/a37f909f1a9e/po-9-e2500033-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/8ed55d7d800a/po-9-e2500033-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/ce3da6820f44/po-9-e2500033-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/94b9bdf11452/po-9-e2500033-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b8ab/12369511/a37f909f1a9e/po-9-e2500033-g004.jpg

相似文献

1
Clinical Significance of Extrachromosomal DNA in -Amplified Gastric Cancer: Therapeutic Implications From Clinical Experience.扩增型胃癌中染色体外DNA的临床意义：基于临床经验的治疗启示
JCO Precis Oncol. 2025 Aug;9:e2500033. doi: 10.1200/PO-25-00033. Epub 2025 Aug 18.
2
FGFR2-amplified tumor clones are markedly heterogeneously distributed in carcinomas of the upper gastrointestinal tract.FGFR2 扩增的肿瘤克隆在上消化道癌中呈显著异质性分布。
J Cancer Res Clin Oncol. 2023 Jul;149(8):5289-5300. doi: 10.1007/s00432-022-04460-w. Epub 2022 Nov 23.
3
FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.FGFR2扩增的胃癌细胞系生长和存活需要FGFR2和Erbb3信号传导。
Cancer Res. 2008 Apr 1;68(7):2340-8. doi: 10.1158/0008-5472.CAN-07-5229.
4
Circulating Tumor DNA Analysis Detects Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer.循环肿瘤 DNA 分析检测晚期胃癌中与 FGFR 抑制剂疗效相关的扩增和同时发生的基因组改变。
Clin Cancer Res. 2021 Oct 15;27(20):5619-5627. doi: 10.1158/1078-0432.CCR-21-1414. Epub 2021 Aug 10.
5
Therapeutic potential of calcitriol in cerebral ischemia/reperfusion injury: In vivo and in silico insights into TLR4 and FGFR2 pathways.骨化三醇在脑缺血/再灌注损伤中的治疗潜力：对TLR4和FGFR2通路的体内及计算机模拟研究
IBRO Neurosci Rep. 2025 Jul 29;19:345-353. doi: 10.1016/j.ibneur.2025.06.018. eCollection 2025 Dec.
6
Extrachromosomal DNA-Driven Oncogene Dosage Heterogeneity Promotes Rapid Adaptation to Therapy in MYCN-Amplified Cancers.染色体外DNA驱动的癌基因剂量异质性促进MYCN扩增癌症对治疗的快速适应。
Cancer Discov. 2025 Aug 7:OF1-OF24. doi: 10.1158/2159-8290.CD-24-1738.
7
Extrachromosomal DNA Dynamics Contribute to Intratumoral Receptor Tyrosine Kinase Genetic Heterogeneity and Drug Resistance in Gastric Cancer.染色体外DNA动态变化促成胃癌瘤内受体酪氨酸激酶基因异质性及耐药性
Mol Cancer Res. 2025 Jun 3;23(6):503-514. doi: 10.1158/1541-7786.MCR-24-0741.
8
Acquired resistance to LY2874455 in FGFR2-amplified gastric cancer through an emergence of novel FGFR2-ACSL5 fusion.通过新型FGFR2-ACSL5融合的出现，FGFR2扩增的胃癌对LY2874455产生获得性耐药。
Oncotarget. 2017 Feb 28;8(9):15014-15022. doi: 10.18632/oncotarget.14788.
9
FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547.胃癌中 FGFR2 基因扩增预示对选择性 FGFR 抑制剂 AZD4547 的敏感性。
Clin Cancer Res. 2013 May 1;19(9):2572-83. doi: 10.1158/1078-0432.CCR-12-3898. Epub 2013 Mar 14.
10
The possible role of epigenetics in the etiology of hypospadias.表观遗传学在尿道下裂病因学中的可能作用。
J Pediatr Urol. 2024 Oct;20(5):877-883. doi: 10.1016/j.jpurol.2024.07.001. Epub 2024 Jul 10.

本文引用的文献

1
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications.针对携带FGFR2扩增的胃癌或胃食管交界癌患者的futibatinib 2期研究。
Eur J Cancer. 2025 Mar 11;218:115262. doi: 10.1016/j.ejca.2025.115262. Epub 2025 Jan 27.
2
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.一种精准肿瘤学中耐药性解码模型：胆管癌对FGFR抑制剂的获得性耐药
Ann Oncol. 2025 Apr;36(4):426-443. doi: 10.1016/j.annonc.2024.12.011. Epub 2024 Dec 18.
3
Enhancing transcription-replication conflict targets ecDNA-positive cancers.
增强转录-复制冲突靶点 ecDNA 阳性癌症。
Nature. 2024 Nov;635(8037):210-218. doi: 10.1038/s41586-024-07802-5. Epub 2024 Nov 6.
4
Origins and impact of extrachromosomal DNA.染色体外 DNA 的起源和影响。
Nature. 2024 Nov;635(8037):193-200. doi: 10.1038/s41586-024-08107-3. Epub 2024 Nov 6.
5
The SCRUM-MONSTAR Cancer-Omics Ecosystem: Striving for a Quantum Leap in Precision Medicine.SCRUM-MONSTAR 癌症组学生态系统：力求在精准医学领域实现飞跃。
Cancer Discov. 2024 Nov 1;14(11):2243-2261. doi: 10.1158/2159-8290.CD-24-0206.
6
Clinical Developments and Challenges in Treating FGFR2-Driven Gastric Cancer.治疗FGFR2驱动的胃癌的临床进展与挑战
Biomedicines. 2024 May 17;12(5):1117. doi: 10.3390/biomedicines12051117.
7
Insight on ecDNA-mediated tumorigenesis and drug resistance.关于染色体外DNA介导的肿瘤发生和耐药性的见解。
Heliyon. 2024 Mar 11;10(6):e27733. doi: 10.1016/j.heliyon.2024.e27733. eCollection 2024 Mar 30.
8
Oncogenic structural aberration landscape in gastric cancer genomes.胃癌基因组中的致癌结构异常全景。
Nat Commun. 2023 Jun 22;14(1):3688. doi: 10.1038/s41467-023-39263-1.
9
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.用于治疗FGFR2重排型肝内胆管癌的futibatinib
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
10
Phase I study of the irreversible fibroblast growth factor receptor 1-4 inhibitor futibatinib in Japanese patients with advanced solid tumors.在日本晚期实体瘤患者中进行不可逆成纤维细胞生长因子受体 1-4 抑制剂 futibatinib 的 I 期研究。
Cancer Sci. 2023 Feb;114(2):574-585. doi: 10.1111/cas.15486. Epub 2022 Dec 4.